LET’S WORK TOGETHER TO ADVANCE PSORIASIS LEADERSHIP TOWARDS A WORLD FREE OF PSORIASIS
Your donations help the IPC achieve our vision of a world free of psoriasis . We are a global network of over 100 psoriasis experts, thought leaders, and professionals, dedicated to improving patient care around the globe. We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
You can support the IPC by providing unrestricted funds through our Corporate Membership program or by sponsoring one of our important education, research or patient care initiatives.
For more information on supporting the International Psoriasis Council, please contact Tina Burke, Corporate Relations Director Tina.Burke@psoriasiscouncil.org
Latest news Video Series on IPC’s Psoriasis Severity ReclassificationMarch 30, 2021Learn how psoriasis severity is currently measured and why a change is necessary, how IPC organized the Delphi process that was used to redefine severity classification, implications and effects the output has on psoriasis treatment providers and psoriasis patients, and ultimately how patients will benefit from this endeavor. Janssen Phase-3 TREMFYA® Clinical TrialMarch 29, 2021Janssen Pharmaceutical Companies of Johnson & Johnson published the long-term data of the third phase of the DISCOVER-2a study. Sun Pharma Phase-3 ILUMYA® Clinical TrialMarch 28, 2021Sun Pharmaceutical Industries Inc. announces results from their five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension. Update on PsoProtect Registry DataMarch 17, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1002 cases. More News